Harlow and London, UK 7th January 2008 – Argenta Discovery Ltd., the pharmaceutical R & D group, has announced that it has entered into a fee-for-service collaboration with Antisoma plc. Under the terms of the agreement, scientists from the two organisations will work together to develop improved molecules for Antisoma’s programme of telomere targeting agents (TTAs). Antisoma will utilise Argenta’s expertise in medicinal chemistry, computer-aided drug design, molecular biology, biochemistry, assay development and in vitro screening, during the course of the collaboration.
Commenting on the agreement, Dr Christopher Ashton, Argenta’s Chief Executive, said, “We are pleased that Antisoma has chosen to collaborate with Argenta on this project. Antisoma’s decision to work with us confirms our contract research team’s experience in undertaking integrated, oncology-focused programmes, and underlines Argenta’s on-going commitment to providing first class contract R & D services to leading organisations in the pharmaceutical industry. We look forward to building a long-term scientific and business relationship with Antisoma.”
Dr Fiona McLaughlin, Director of Research at Antisoma said, "We are looking forward to working with Argenta on the TTA project. This is part of our effort to add new candidates to the promising tumour-targeting therapeutics we already have in the clinic. Argenta is well-known and respected within the pharmaceutical industry for its high-quality medicinal chemistry services, and was therefore a natural choice as partner for this work.”
Financial terms of the deal were not disclosed, but the agreement does provide options to expand the relationship.
Notes to Editors:
Argenta Discovery was founded in August 2000. Its contract research division provides integrated drug discovery services, comprising medicinal chemistry, computer-aided drug design (CADD), biochemistry, in vitro screening and early ADME, to a range of leading pharmaceutical and biotechnology companies world-wide. Argenta’s industry experienced scientists deliver rapid hit finding capabilities and have the skills to discover, convert and optimise hits and leads into potential drug candidates quickly and effectively.
Argenta Discovery also has leading expertise in chronic respiratory diseases including Chronic Obstructive Pulmonary Disease (COPD), Asthma and Cystic Fibrosis. Argenta is developing a number of internal proprietary programmes in COPD with the goal of taking these as far as Phase IIa ‘proof-of-concept’ before partnering.
Argenta employs 160 people and is based in Harlow, Essex; Welwyn Garden City, Herts., and Slough, Berks., UK. For additional information about the company, please visit www.argentadiscovery.com
Headquartered in London, UK, Antisoma is a biopharmaceutical company that develops novel products for the treatment of cancer. Antisoma fills its development pipeline by acquiring promising new product candidates from internationally recognised academic or cancer research institutions. Its core activity is the pre-clinical and clinical development of these drug candidates. Please visit www.antisoma.com for further information about Antisoma.
Christopher Ashton, PhD
Argenta Discovery Ltd.
Tel: + 44 1279 645 645
©2008 Argenta Discovery™. All rights reserved.
Argenta Discovery Limited is a company incorporated and registered in England with registered number 3671653 whose registered office and principal place of business is at 8/9 Spire Green Centre, Flex Meadow, Harlow, CM19 5TR, United Kingdom, and whose VAT registration number is GB 848 2268 02.